首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Unique product quality considerations in vaccine development registration and new program implementation in Malaysia
【2h】

Unique product quality considerations in vaccine development registration and new program implementation in Malaysia

机译:马来西亚疫苗开发注册和新计划实施中独特的产品质量考虑

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This review aims to present the unique considerations for manufacturing and the regulation of new vaccines in Muslim-populated countries such as Malaysia. Our specific objectives are to highlight vaccine production and the ingredients of concern, summarize the current mechanism for ruling and recommendations on new vaccines, outline the different steps in decision-making on incorporating a new vaccine into the National Immunization Program, describe its issues and challenges, and explore the commercial viability and challenges of producing local permissible ( vaccines. Through this review, we hope readers understand that alternatives are present to replace ingredients of concern in vaccines. certification and introduction of a new vaccine into a program are strictly conducted and health-care providers must be prepared to educate the public on this. At the same time, it is hoped that the production of vaccine in Malaysia will promote self-reliance in Muslim-populated countries.
机译:这篇综述旨在介绍在穆斯林人口稠密的国家(例如马来西亚)生产和管理新疫苗的独特考虑。我们的具体目标是突出疫苗的生产和关注的成分,总结当前对新疫苗的裁决机制和建议,概述将新疫苗纳入国家免疫计划的决策步骤,描述其问题和挑战,并探讨生产当地允许的疫苗的商业可行性和挑战。通过这次审查,我们希望读者能够理解存在替代品来替代疫苗中关注的成分。严格进行认证和将新疫苗引入计划中,并且保持健康护理人员必须准备就此进行教育,与此同时,希望在马来西亚生产疫苗可以促进穆斯林人口密集国家的自力更生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号